Massachusetts Financial Services Co. MA Sells 5,336 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Massachusetts Financial Services Co. MA trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,703 shares of the medical research company's stock after selling 5,336 shares during the period. Massachusetts Financial Services Co. MA owned 0.07% of IQVIA worth $31,921,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. PGGM Investments raised its stake in shares of IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company's stock worth $2,553,000 after acquiring an additional 4,326 shares during the last quarter. Simplify Asset Management Inc. lifted its stake in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after acquiring an additional 3,894 shares during the period. Raymond James & Associates grew its position in shares of IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock worth $169,231,000 after buying an additional 5,417 shares during the period. Versor Investments LP bought a new stake in shares of IQVIA during the third quarter worth approximately $1,328,000. Finally, Gradient Investments LLC lifted its holdings in IQVIA by 15.6% in the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock valued at $9,600,000 after buying an additional 6,134 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 1.4 %

NYSE:IQV traded down $2.78 on Tuesday, hitting $201.24. 1,370,041 shares of the company's stock were exchanged, compared to its average volume of 1,178,988. The company has a market cap of $36.53 billion, a P/E ratio of 26.41, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51. The firm has a 50-day moving average price of $221.18 and a 200-day moving average price of $226.75. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Redburn Atlantic began coverage on IQVIA in a report on Monday, October 14th. They set a "buy" rating and a $276.00 target price on the stock. Argus upgraded shares of IQVIA to a "strong-buy" rating in a report on Wednesday, July 31st. Evercore ISI cut their target price on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Leerink Partners reissued an "outperform" rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.